IL131004A0 - Il-8 receptor antagonists - Google Patents

Il-8 receptor antagonists

Info

Publication number
IL131004A0
IL131004A0 IL13100498A IL13100498A IL131004A0 IL 131004 A0 IL131004 A0 IL 131004A0 IL 13100498 A IL13100498 A IL 13100498A IL 13100498 A IL13100498 A IL 13100498A IL 131004 A0 IL131004 A0 IL 131004A0
Authority
IL
Israel
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Application number
IL13100498A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL131004A0 publication Critical patent/IL131004A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65848Cyclic amide derivatives of acids of phosphorus, in which two nitrogen atoms belong to the ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
IL13100498A 1997-01-23 1998-01-23 Il-8 receptor antagonists IL131004A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3599197P 1997-01-23 1997-01-23
US4282997P 1997-04-08 1997-04-08
PCT/US1998/001291 WO1998032439A1 (fr) 1997-01-23 1998-01-23 Antagonistes du recepteur de l'il-8

Publications (1)

Publication Number Publication Date
IL131004A0 true IL131004A0 (en) 2001-01-28

Family

ID=26712688

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13100498A IL131004A0 (en) 1997-01-23 1998-01-23 Il-8 receptor antagonists

Country Status (15)

Country Link
US (1) US6300325B1 (fr)
EP (1) EP0991406A4 (fr)
JP (1) JP2001511130A (fr)
KR (1) KR20000070368A (fr)
CN (1) CN1217660C (fr)
AU (1) AU726858B2 (fr)
BR (1) BR9807083A (fr)
CA (1) CA2278504A1 (fr)
HU (1) HUP0001943A3 (fr)
IL (1) IL131004A0 (fr)
NO (1) NO313961B1 (fr)
NZ (1) NZ336861A (fr)
PL (1) PL334756A1 (fr)
TR (1) TR199901710T2 (fr)
WO (1) WO1998032439A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0932405A4 (fr) 1996-06-27 2001-10-17 Smithkline Beckman Corp Antagonistes des recepteurs d'il-8
WO1999065310A1 (fr) * 1998-06-17 1999-12-23 Smithkline Beecham Corporation Antagonistes des recepteurs d'il-8
DE19842363A1 (de) * 1998-09-16 2000-03-30 Forssmann Wolf Georg Verwendung von Chemokinen zur Stammzellmobilisation und von Chemokin-Antagonisten zur Vermeidung von Tumormetastasierung
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (fr) 1999-01-13 2012-05-09 Bayer HealthCare LLC Urées de diphényle à substitution omega-carboxyaryle en tant qu'inhibiteurs de la p38 kinase
CO5170514A1 (es) 1999-05-28 2002-06-27 Smithkline Beecham Corp Antagonistas de los receptores de la il-8 nistas del receptor de la il-8
CO5190696A1 (es) * 1999-06-16 2002-08-29 Smithkline Beecham Corp Antagonistas de los receptores il-8
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
US20030204085A1 (en) * 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) * 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
NZ551453A (en) 2001-04-18 2008-02-29 Euro Celtique Sa Nociceptin analogs for the treatment of pain
CA2462862A1 (fr) * 2001-10-12 2003-04-17 Schering Corporation Composes de maleimide di-substitues en 3,4, antagonistes du recepteur de la cxc-chimiokine
US6878709B2 (en) * 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
MXPA04009127A (es) * 2002-03-18 2005-01-25 Schering Corp Tratamiento de enfermedades mediadas por quimiocinas.
US7115644B2 (en) * 2002-09-13 2006-10-03 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds
PE20040570A1 (es) * 2002-10-09 2004-08-30 Pharmacopeia Drug Discovery Tiadiazoldioxidos y tiadiazoloxidos como ligandos del receptor de cxc- y cc-quimiocina
TW200418812A (en) * 2002-10-29 2004-10-01 Smithkline Beecham Corp IL-8 receptor antagonists
JP2007511203A (ja) 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
SI1663978T1 (sl) 2003-07-23 2008-02-29 Bayer Pharmaceuticals Corp Fluoro substituirana omega-karboksiaril difenil secnina za zdravljenje ali preprecevanje bolezni instanj
MXPA06007076A (es) * 2003-12-19 2006-08-31 Pharmacopeia Drug Discovery Tiadiazoles como ligandos del receptor cxc y cc-quimiocina.
MXPA06007205A (es) * 2003-12-22 2006-08-31 Schering Corp Dioxidos de isotiazol como ligandos del receptor cxc y cc-quimiocina.
GB0403038D0 (en) 2004-02-11 2004-03-17 Novartis Ag Organic compounds
CN1984899B (zh) 2004-05-12 2011-07-27 先灵公司 Cxcr1和cxcr2趋化因子拮抗剂
US20070249625A1 (en) * 2004-10-20 2007-10-25 Jakob Busch-Petersen Il-8 Receptor Antagonists
CA2580690A1 (fr) * 2004-10-21 2006-05-04 Transtech Pharma, Inc. Composes bissulfonamide utilises en tant qu'agonistes du galr1, compositions, et procedes d'utilisation associes
CN101253165A (zh) * 2005-06-29 2008-08-27 先灵公司 作为cxc-化学活素受体配体的二取代的二唑
MX2008000367A (es) * 2005-06-29 2008-03-07 Schering Corp Oxidiazolopirazinas y tiadiazolopirazinas 5,6-di-sustituidas como ligandos de receptor de quimiocina en la que dos cisternas son separadas por un solo aminoacido.
US8097626B2 (en) * 2006-04-21 2012-01-17 Glaxosmithkline Llc IL-8 receptor antagonists
UA98456C2 (en) * 2006-04-21 2012-05-25 Смитклайн Бичам Корпорейшн Il-8 receptor antagonists
TW200817006A (en) * 2006-06-23 2008-04-16 Smithkline Beecham Corp IL-8 receptor antagonist
TW200813033A (en) * 2006-07-07 2008-03-16 Schering Corp 3, 4-di-substituted cyclobutene-1, 2-diones as CXC-chemokine receptor ligands
CN102066372B (zh) 2009-08-24 2014-09-17 苏州爱斯鹏药物研发有限责任公司 含脲基的5,6元杂芳双环化合物作为激酶抑制剂
CN111362878B (zh) * 2020-03-18 2023-09-19 湖南复瑞生物医药技术有限责任公司 一种4-氨基-1,3-二氢-苯并咪唑-2-酮的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK160941C (da) * 1988-06-28 1991-10-21 Novo Nordisk As Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar
WO1996025157A1 (fr) * 1995-02-17 1996-08-22 Smithkline Beecham Corporation Antagonistes des recepteurs d'il-8
JP2000515495A (ja) * 1996-06-27 2000-11-21 スミスクライン・ビーチャム・コーポレイション Il―8レセプターアンタゴニスト
WO1997049399A1 (fr) * 1996-06-27 1997-12-31 Smithkline Beecham Corporation Antagonistes des recepteurs d'il-8

Also Published As

Publication number Publication date
WO1998032439A1 (fr) 1998-07-30
CN1217660C (zh) 2005-09-07
US6300325B1 (en) 2001-10-09
HUP0001943A2 (hu) 2001-01-29
CN1251038A (zh) 2000-04-19
TR199901710T2 (xx) 1999-09-21
PL334756A1 (en) 2000-03-13
NO993586D0 (no) 1999-07-22
HUP0001943A3 (en) 2002-12-28
NZ336861A (en) 2001-01-26
EP0991406A4 (fr) 2000-12-13
NO313961B1 (no) 2003-01-06
AU726858B2 (en) 2000-11-23
BR9807083A (pt) 2000-04-18
KR20000070368A (ko) 2000-11-25
AU6133998A (en) 1998-08-18
CA2278504A1 (fr) 1998-07-30
EP0991406A1 (fr) 2000-04-12
JP2001511130A (ja) 2001-08-07
NO993586L (no) 1999-09-21

Similar Documents

Publication Publication Date Title
IL134855A0 (en) Il-8 receptor antagonists
IL131004A0 (en) Il-8 receptor antagonists
IL127666A0 (en) IL-8 receptor antagonists
IL127667A0 (en) IL-8 receptor antagonists
EP0932405A4 (fr) Antagonistes des recepteurs d'il-8
EP0896531A4 (fr) Antagonistes de recepteurs de l'interleukine-8
IL128501A0 (en) IL-8 receptor antagonists
EP1000017A4 (fr) Antagonistes du recepteur il-8
EP0907362A4 (fr) Antagonistes des recepteurs d'il-8
EP1019035A4 (fr) Antagonistes du recepteur d'il-8
EP0920417A4 (fr) Antagonistes du recepteur de l'il-8
IL131005A0 (en) Il-8 receptor antagonists
IL134854A0 (en) Il-8 receptor antagonists
EP0971908A4 (fr) Antagoniste de recepteurs d'il-8
EP0923373A4 (fr) Antagonistes du recepteur d'il-8
EP0939634A4 (fr) Antagonistes du recepteur il-8
EP0957907A4 (fr) Antagonistes du recepteur de l'il-8
EP0934066A4 (fr) Antagonistes du recepteur de l'interleukine-8 (il-8)
EP1039903A4 (fr) Antagonistes des recepteurs de l'interleukine-8
EP1047424A4 (fr) Antagonistes des recepteurs il-8
EP0920253A4 (fr) Antagonistes du recepteur il-8
EP0948330A4 (fr) Antagonistes du recepteur d'il-8
IL140983A0 (en) Il-8 receptor antagonists
ZA98519B (en) Il-8 receptor antagonists
HUP9904303A3 (en) Il-8 receptor antagonists